STING activation synergizes with VEGF receptor 2 (VEGFR-2) blockade, leading to normalization of the tumor vasculature, upregulation of VCAM-1 and ICAM-1, and regression of immunotherapy-resistant tumors (35). The gene discussed is ICAM1; the disease is neoplasm.